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ABSTRACT
Objective To investigate the risk of incident myocardial
infarction, congestive heart failure, and all cause
mortalityassociatedwithprescriptionoforalantidiabetes
drugs.
Design Retrospective cohort study.
Setting UK general practice research database,
1990-2005.
Participants 91521 people with diabetes.
Main outcome measures Incident myocardial infarction,
congestive heart failure, and all cause mortality. Person
timeintervalsfordrugtreatmentwerecategorisedbydrug
class, excluding non-drug intervals and intervals for
insulin.
Results 3588 incident cases of myocardial infarction,
6900 of congestive heart failure, and 18548 deaths
occurred. Compared with metformin, monotherapy with
firstorsecondgenerationsulphonylureaswasassociated
with a significant 24% to 61% excess risk for all cause
mortality (P<0.001) and second generation
sulphonylureas with an 18% to 30% excess risk for
congestive heart failure (P=0.01 and P<0.001). The
thiazolidinediones were not associated with risk of
myocardialinfarction;pioglitazonewasassociatedwitha
significant 31% to 39% lower risk of all cause mortality
(P=0.02toP<0.001)comparedwithmetformin.Amongthe
thiazolidinediones, rosiglitazone was associated with a
34% to 41% higher risk of all cause mortality (P=0.14 to
P=0.01) compared with pioglitazone. A large number of
potential confounders were accounted for in the study;
however, the possibility of residual confounding or
confounding by indication (differences in prognostic
factors between drug groups) cannot be excluded.
Conclusions Our findings suggest a relatively
unfavourable risk profile of sulphonylureas compared
with metformin for all outcomes examined. Pioglitazone
was associated with reduced all cause mortality
compared with metformin. Pioglitazone also had a
favourable risk profile compared with rosiglitazone;
although this requires replication in other studies, it may
have implications for prescribing within this class of
drugs.
INTRODUCTION
More than 180 million people worldwide have type 2
diabetes, a disease associated with at least double the
risk of death, mainly from cardiovascular disease.
1
Oralantidiabetesdrugsarecommonlyusedtoimprove
glycaemic control, but there are concerns that some
may increase the risk ofcardiovascular events.
2-11 Thia-
zolidinediones, for example, were initially approved as
glucose loweringagentswitha beneficial effectoninsu-
lin sensitivity and a potential beneficial effect on risk of
cardiovascular disease. The initial enthusiasm for this
class of drugs was, however, soon tempered by the
observation in several clinical trials that rosiglitazone
andpioglitazonewereassociatedwithanincreasedinci-
dence of congestive heart failure, resulting in a black
box warning against the use of these drugs in patients
with pre-existing congestive heart failure.
2 Am e t a - a n a -
lysis of data from clinical trials then found an increased
risk of myocardial infarction and death from cardio-
vascular causes in relation to use of rosiglitazone,
althoughafurthermeta-analysisandotherstudiesfailed
to replicate this result.
3-5 The mortality associated with
these drugs and their net benefit on cardiovascular
events is still highly debated. This debate is set against
a background of uncertainty about the cardiovascular
safety of another class of oral antidiabetes drugs—sul-
phonylureas—with some studies suggesting an adverse
effect and others no effect.
12
Given the common and increasing use of anti-
diabetesdrugs,itisessentialtodeterminetheirrelative
benefits and disadvantages to cardiovascular health.
Analyses of observational data examining risks asso-
ciated with use of antidiabetes drugs among patients
attending general practice are limited,
13-16 but such
“phase IV” studies are an important additional step in
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17 Phase III randomised controlled
trials are often too small and of too short a duration to
detect small or cumulative adverse effects and are
necessarily prescriptive in their choice of patients for
entry into trials. In contrast, surveillance data through
general practice are able to capture information on
drugs and events routinely on a wide range of patients
as they present for clinical care. This is an important
strength that cannot be captured in other ways.
We investigated the risk of myocardial infarction,
congestive heart failure, and all cause mortality asso-
ciatedwithprescriptionofdifferentclassesoforalanti-
diabetes drugs among men and women with diabetes
included in the general practice research database in
the United Kingdom. A previous analysis of the data-
base based on a much smaller patient population
focused on risk of congestive heart failure among
users of older oral antidiabetes drugs and insulin.
16
We aimed to expand these data by studying a much
larger patient population (n=91521) and a range of
cardiovascular and other outcomes, and to examine
the risks associated with the thiazolidinediones rosigli-
tazone and pioglitazone.
METHODS
Thegeneralpracticeresearchdatabasecomprisesclin-
ical and prescribing data from anonymised patient
based clinical records of about five million people.
1718
Weobtaineddataonpatientsaged35-90yearswithan
episodeofcarebetween1January1990and31Decem-
ber 2005 and a diagnostic (Read) code associated with
a clinical or referral event for diabetes. We excluded
those records with multiple or missing date of death
(see web extra appendix).
Definition of events and drug treatments
Primary events were first occurrence of incident myo-
cardialinfarction,congestiveheartfailure,andallcause
mortality. Events were identified by Read codes (see
web extra appendix tables 1-3). Validation studies
within the general practice researchdatabase have con-
firmed about 83-90% of diagnoses for myocardial
infarctionandcongestiveheartfailure.
1619Weincluded
fractures (non-hip) as a positive control because of the
known association between thiazolidinedione use and
risk of fractures.
20 We identified oral antidiabetes treat-
ments of individual patients from prescription records:
rosiglitazone monotherapy, rosiglitazone combination
therapy (with other antidiabetes drugs), pioglitazone
monotherapy, pioglitazone combination therapy, met-
formin monotherapy, monotherapy with first genera-
tion sulphonylureas (acetohexamide, chlorpropamide,
tolbutamide,ortolazamide),monotherapywith second
generation sulphonylureas (glipizide, gliquidone, gli-
mepiride, glibenclamide, or gliclazide), other oral anti-
diabetes drugs (for example, acarbose, nateglinide,
repaglinide),andcombinationtherapiesexcludingthia-
zolidinediones and insulin. As the pioglitazone mono-
therapygroupwassmall,weanalyseditjointlywiththe
pioglitazone combination group. We excluded
untreated patients, without prescriptions for anti-
diabetes treatment, from further analyses.
Data analysis
We used an interval of drug treatment as the unit of
observation, defined as the period from onset of a
drug treatment to onset of the next drug treatment, or
untilcensoredoruntiloccurrenceoftheeventofinter-
est. For example, a patient prescribed monotherapy
with sulphonylureas at entry to the cohort then pre-
scribed a combination of sulphonylurea and metfor-
min and remaining on that combination therapy until
a myocardial infarction occurred, or until censored,
wasconsideredtohavecontributedatotaloftwointer-
vals. Similarly, if a patient was prescribed monother-
apywithsulphonylureasatentrytothecohortandthen
continued taking sulphonylurea but was also pre-
scribed aspirin, a new drug interval was calculated. In
totaltherewere 2843007intervalsoforalantidiabetes
treatments among 91521 patients with diabetes. We
excluded periods when patients received insulin ther-
apy, and events throughout these periods.
We used Cox regression stratified by age at diagno-
sis (quartiles) and calendar year of prescription to
accountforseculartrendsineventsunderstudy.Alter-
native models stratifying by either age at diagnosis
(continuous) or duration of diabetes or adjusting for
age at diagnosis (continuous) resulted in similar risk
estimates. Censoring was at the end of each period of
constantprescription (or the end of the study). As met-
formin is advocated as first line pharmacotherapy for
type 2 diabetes we compared the risk associated with
each drug or drug class with that of metformin
monotherapy.
2122 We also compared risks among the
thiazolidinediones. Analyses were further adjusted,
sequentially, for sex and duration of diabetes (model
1); plus previous complications from diabetes, pre-
vious peripheral artery disease, previous cardio-
vascular disease, and coprescribed drugs (model 2);
plus body mass index, cholesterol concentration, sys-
tolic blood pressure, HbA1c level, creatinine concen-
tration, albumin concentration, and smoking status
(model 3). Covariates were reascertained at the onset
of each interval except for sex and smoking, which
were ascertained only at baseline. Data on model 2
were missing for 503 to 169103 intervals. For model
3 we included the first non-missing measurement dur-
ing the prescription interval. If this was not available,
we used the most recent preceding measurement if
available, dating back to baseline (909367 to 948800
intervals). Overall, 28812 patients had missing values
of at least one covariate used in model 3 and therefore
were excluded from that analysis.
Sensitivity analyses included an analysis of prescrip-
tionsforsecondgenerationsulphonylureasonly(asimi-
lar analysis was not feasible for first generation
sulphonylureas owing to small numbers), adjustment
for cumulative past prescriptions of antidiabetes drugs
prescribed from the start of the study period until the
beginningofeachdruginterval,onlydrugprescriptions
afterintroductionofthiazolidinediones(≥2000)intothe
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scription for oral antidiabetes drug, sex specific ana-
lyses, and subgroup analyses by thirds of duration of
diabetes before drug treatment. To explore possible
interactions we fitted interaction terms (model 2) sepa-
rately for each drug or drug class by age (>65 or ≤65),
sex, aspirin use, and statin or fibrate use.
Statistical analysis was done by IT and MPL using
SAS v9.0 and SPSS v15.0. A two sided P value of
0.05wasusedtodenotesignificance.Wefoundnoevi-
denceforviolationoftheproportionalhazardassump-
tion, assessed by testing for a non-zero slope of the
scaled Schoenfeld residuals on functions of time.
RESULTS
The mean(SD) ageof the 91521 people receiving oral
antidiabetes agents was 65.0 (11.9) years. The median
follow-up period was 24 days (interquartile range
13-42 days) per interval and the mean follow-up per
individual was 7.1 years. During the study period
there were 3588 first events of myocardial infarction,
6900 first events of congestive heart failure, 18548
deaths,and2123fractures.Amongalldrugtreatments,
metformin monotherapy was most commonly pre-
scribed (74.5% of patients), followed by monotherapy
with second generation sulphonylureas (63.5%;
table 1). Table 1 shows the patients’ characteristics
according to drug prescriptions.
Myocardial infarction
Firstandsecondgenerationsulphonylureaswereasso-
ciated with a significant excess risk of a first episode of
myocardial infarction compared with metformin
monotherapy in models 1 and 2: the adjusted hazard
ratio ranged from 1.37 (95% confidence interval 1.15
to 1.62) to 1.27 (1.07 to 1.50) for first generation sul-
phonylureas and from 1.31 (1.21 to 1.43) to 1.25 (1.15
to1.36)forsecondgenerationsulphonylureas(table 2,
figure).Theexcessriskassociatedwithsulphonylureas
was observed for all subclasses of second generation
drugs (see web extra appendix table 4). In the fully
adjusted model (model 3), based on 30% of intervals,
point estimates for risk of myocardial infarction for
both first and second generation drug groups were
still above 1, although these hazard ratios were no
longerstatisticallysignificant.(Inevaluatingtheeffects
of additional adjustment for confounders in model 3
comparedwithmodels1and2,themuchreducedsam-
ple size consequent on use of model 3 should be con-
sidered in interpreting these non-significant results).
Rosiglitazone, either alone or in combination,
showed no significant association with incidence of
Table 1 |Characteristics of drug treatment intervals at onset of each interval. Values are means (standard deviations) unless stated otherwise
Variables
Drug treatment intervals
First generation
sulphonylureas
Second
generation
sulphonylureas Rosiglitazone
Rosiglitazone
combination
Pioglitazone
monotherapy or
combination
Other drugs or
combinations Metformin
No of intervals 85 156 988 356 47 695 92 387 45 807 533 897 1 049 709
No of patients 6053 58 095 8442 9640 3816 37 253 68 181
Men (%) 48.6 52.6 50.5 53.6 54.3 53.6 50.6
Age at prescription (years) 73.2 (10.3) 70.4 (10.7) 65.7 (10.9) 64.5 (10.8) 64.8 (10.6) 67.4 (10.5) 66.3 (10.8)
Age at diagnosis of diabetes (years) 64.5 (11.4) 63.5 (11.2) 58.6 (10.8) 57.0 (10.4) 57.7 (10.4) 58.3 (10.5) 60.4 (11.0)
Duration of diabetes at prescription (years) 8.5 (7.4) 6.6 (6.4) 6.7 (6.0) 7.1 (6.1) 6.7 (5.8) 8.8 (6.7) 5.59 (6.1)
Previous prescription:
Metformin monotherapy (%) 11.8 19.6 44.1 40.2 40.8 42.2 —
First generation sulphonylureas (%) — 1.9 2.7 2.6 1.6 5.1 1.9
Second generation sulphonylureas (%) 7.7 — 33.3 30.5 32.1 42.2 19.2
Thiazolidinediones (%) 0.6 2.0 ——— 1.8 2.4
Body mass index (kg/m
2) 27.8 (4.9) 28.5 (5.2) 31.7 (6.6) 31.8 (6.5) 31.9 (6.3) 30.1 (5.7) 31.47 (6.0)
Systolic blood pressure (mm Hg) 151.3 (23.1) 147.0 (21.7) 143.2 (19.4) 142.1 (18.8) 141.6 (18.4) 146.5 (20.8) 144.7 (19.8)
Cholesterol concentration (mmol/l) 5.7 (1.3) 5.4 (1.3) 5.3 (1.34) 5.2 (1.3) 5.2 (1.3) 5.3 (1.3) 5.24 (1.3)
Creatinine concentration (μmol/l) 104.4 (30.8) 100.0 (29.8) 94.1 (27.7) 91.5 (24.6) 93.9 (25.8) 93.7 (24.1) 91.77 (22.5)
HbA1c level (%) 8.1 (2.1) 8.2 (2.0) 8.4 (1.8) 8.5 (1.8) 8.4 (1.8) 8.4 (2.0) 8.13 (1.8)
Current smoker (%) 10.2 12.5 11.5 13.1 14.1 12.7 13.8
Aspirin (%) 16.6 17.7 14.5 29.8 24.9 23.8 20.1
Statin or fibrate (%) 8.8 18.2 28.5 50.9 40.8 28.4 29.2
ACE inhibitors or angiotensin II receptor
blockers (%)
18.4 24.5 26.4 45.0 38.0 33.6 30.3
NSAIDS (%) 25.2 24.5 18.7 36.2 30.7 31.2 26.6
Clinical history:
Diabetes complications (%) 10.2 14.5 25.3 25.3 25.2 19.7 15.1
Cardiovascular disease (%) 15.0 16.5 15.5 14.5 15.4 17.6 13.4
Peripheral arterial disease (%) 3.5 2.8 3.0 2.9 2.5 3.4 2.1
ACE=angiotensin converting enzyme; NSAIDS=non-steroidal anti-inflammatory drugs.
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monotherapy in all models; hazard ratios ranged from
0.79 (0.41 to 1.53) in the fully adjusted model 3 to 0.94
(0.62 to 1.43) in the minimally adjusted model 1 for
monotherapy and 0.82 (0.56 to 1.20) to 1.08 (0.86 to
1.36) for combination therapy, respectively. Pioglita-
zone was associated with a non-significant reduced
risk of myocardial infarction, which ranged from 22%
in both model 1 and model 2 to 29% in the fully
adjustedmodel3(table 2andfigure).Whencompared
with pioglitazone (either monotherapy or in combina-
tion with other oral antidiabetes drugs) rosiglitazone
was associated with 34% (model 1) to 14% (model 3)
non-significant higher risks of myocardial infarction
(figure, and see web extra appendix figures 1a and
2a). Otherdrugs and combination therapies excluding
thiazolidinediones were associated with an excess risk
of myocardial infarction compared with metformin,
although this was not the case in the fully adjusted
model 3 (table 2 and figure, and see web extra appen-
dix figures 1a and 2a).
Congestive heart failure
Comparedwithmetforminmonotherapy,firstgenera-
tion sulphonylureas were associated with a significant
excess risk of a first episode of congestive heart failure
inmodels1and2;hazardratiosrangedfrom1.29(1.17
to1.44)to1.46(1.32to1.63;table 3andfigure).Inthe
fully adjusted model 3, however, associations became
non-significant,possiblyreflectingthereducedsample
size and small numbers of events in this analysis. Sec-
ond generation sulphonylureas were associated with a
significant excess risk of congestive heart failure in all
models, with hazard ratios ranging from 1.18 (1.04 to
1.34) in model 3 to 1.30 (1.22 to 1.38) in model 1. The
subclasses of second generation sulphonylureas were
associated with an excess risk of congestive heart fail-
ure in most analyses (see web extra appendix tables 4-
6). Individuals prescribed rosiglitazone combination
therapyhadasignificantexcessriskofdevelopingcon-
gestive heart failure compared with those prescribed
metformin monotherapy in models 1 and 2; hazard
ratios ranged from 1.27 (1.06 to 1.53) in model 2 to
1.31 (1.09 to 1.58) in model 1 (table 3 and figure).
The association, however, lost statistical significance
in the fully adjusted model 3. Pioglitazone monother-
apyorcombinationtherapywasassociatedwithanon-
significant excess risk of heart failure, ranging from
1.17 (0.77 to 1.77) in model 3 to 1.18 (0.88 to 1.57) in
model 1.
All cause mortality
Sulphonylureas, either first or second generation, were
associatedwithanincreasedriskofmortalitycompared
with metformin alone in all models examined. Hazard
ratios for first generation sulphonylureas were higher
than for second generation sulphonylureas and ranged
from1.37(1.11to1.71)forthefullyadjustedmodel3to
1.61 (1.49 to1.74) adjusted for age, sex, year, and dura-
tion of diabetes in model 1 (table 4, figure). Risks were
higher at younger compared with older ages (see web
extraappendixtables 7and8).Rosiglitazonecombina-
tion therapy was associated with a reduced risk of all
cause mortality compared with metformin, as was pio-
glitazone alone andcombined.Hazard ratiosforpiogli-
tazone attained statistical significance in all models and
ranged from 0.69 (0.49 to 0.98, P=0.024) in model 3 to
0.61 (0.47 to 0.80, P=0.0003) in model 1. Among the
thiazolidinediones, rosiglitazone was associated with a
higher risk of all cause mortality than pioglitazone;
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Risk of myocardial infarction, congestive heart failure, and all
cause mortality for different comparisons of drug groups.
Analysis is stratified by year of prescription and quartiles of
age at treatment, and adjusted for sex, duration of diabetes,
previous peripheral arterial disease, previous cardiovascular
disease, aspirin, statin or fibrate, diuretics, calcium channel
blockers, spironolactone, β adrenergic antagonists,
angiotensin converting enzyme inhibitors or angiotensin II
receptor blockers, nitrates, steroids, non-steroidal anti-
inflammatory drugs, digoxin, and any previous complications
from diabetes (model 2). *Any therapy (monotherapy and
combinations). †Other drugs and combinations of any oral
antidiabetes drugs excluding rosiglitazone and pioglitazone
RESEARCH
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to 1.34 (0.90 to 1.97) in model 3 (figure and see web
extra appendix figures 1 and 2).
Findingswere similar when analyses were limited to
drug prescriptions from 2000 onwards after introduc-
tion of thiazolidinediones and when analyses were
adjusted for the cumulative dose of all other previous
prescriptions of oral antidiabetes drugs (see web extra
appendixtables 9and10).Sensitivityanalysesformen
and women, for different duration of disease before
treatment, and for inclusion of recurrent events are
presented in web extra appendix tables 11-16, and
tests of interaction in web extra appendix table 17.
Fractures
Thiazolidinedioneswereassociatedwithanexcessrisk
of non-hip fractures compared with metformin alone.
After adjustment for confounders, there was a 53%
excessriskforrosiglitazonecombinationtherapycom-
pared with metformin alone (hazard ratio 1.53, 1.25 to
1.88, P<0.001; see web extra appendix table 18). Pio-
glitazone was associated with a non-significant excess
risk (hazard ratio 1.28, 0.93 to 1.77; P=0.127).
DISCUSSION
Ourstudypresentsobservationaldatafromlargenum-
bers of patients with type 2 diabetes attending for rou-
tine clinical care in general practice in the UK. We
reportimportantdifferencesinriskassociatedwithdif-
ferent classes of oral antidiabetes drugs. Compared
with metformin, monotherapy with either first or sec-
ond generation sulphonylureas was associated with a
significantexcessriskofallcausemortality,andsecond
generation sulphonylureas with an excess risk of con-
gestive heart failure. The thiazolidinediones were not
associatedwithriskofmyocardialinfarction;therewas
a significantly lower risk of all cause mortality asso-
ciated with pioglitazone use compared with metfor-
min. Among the thiazolidinediones, a higher risk of
allcausemortalitywasobservedforrosiglitazonecom-
pared with pioglitazone; however, risk was not signifi-
cant in the fully adjusted model.
Strengths and weaknesses of the study
Our study of observational data in general practice
allows assessment of the relative benefits and hazards
of use of oral antidiabetes drugs in a “real world” clin-
ical setting.
A diagnosis of cardiovascular disease in the general
practice research database has been shown to have
highvalidity.
1619Ouranalysesofthedatabaseinvolved
about three million intervals of drug treatments, with
ascertainment of drug co-prescriptions and covariates
at the beginning of each interval. This enabled us to
account for switching of drugs and timing of treat-
ments, make extensive adjustments for covariates,
and provide prognostic information associated with
different drug therapies. We used metformin mono-
therapy as a common reference group, in contrast
with the meta-analyses of data from clinical trials that
pooled results across studies with varying drug and
non-drug reference groups, introducing possible het-
erogeneity into those analyses.
We assumed that a drug prescription interval
equates to the patient taking the drug, whereas it is
well known that there is variable adherence with pre-
scribed treatments.
23 Also, we assumed that patients
were prescribed more than one oral antidiabetes treat-
mentifmorethanonedrugwasprescribedonthesame
date. In a few cases the second drug might have been
prescribed some days later. On the basis that these
assumptions lead to non-systematic misclassification
errors, they may result in underestimation of true
effects, although overestimation is also possible since,
for example, specific groups of patients (with varying
morbidities)maybemoreorlesslikelytocomplywith
prescribed treatments.
23
As with any observational study, the possibility of
residualconfoundingorconfoundingbyindication(dif-
ferences in prognostic factors between different drug
groups)cannotbeexcluded.Thismayresultinspurious
associations of drug with events. We guarded against
thispossibilitybycarefulsequentialbuildingofmodels,
including a large number of potential confounders in
our analyses, and we included fractures as a positive
control because of the well known association with
thiazolidinediones.Wepresentedmodelsbothadjusted
and unadjusted for potential confounders as some fac-
tors, such as body mass index, may be considered
Table 2 |Risk of a first episode of myocardial infarction among patients receiving
rosiglitazone, pioglitazone, sulphonylureas, and other drugs and combinations compared
with patients receiving metformin alone
Models and treatments No of events Hazard ratio (95% CI) P value
Model 1 (2 761 889 intervals):
First generation sulphonylureas 170 1.37 (1.15 to 1.62) 0.0003
Second generation sulphonylureas 1575 1.31 (1.21 to 1.43) <0.001
Rosiglitazone 23 0.94 (0.62 to 1.43) 0.783
Rosiglitazone combination 83 1.08 (0.86 to 1.35) 0.524
Pioglitazone alone and combined 24 0.78 (0.52 to 1.17) 0.230
Other drugs and combinations 793 1.19 (1.08 to 1.31) 0.0007
Model 2 (2 761 889 intervals):
First generation sulphonylureas 170 1.27 (1.07 to 1.50) 0.007
Second generation sulphonylureas 1575 1.25 (1.15 to 1.36) <0.001
Rosiglitazone 23 0.97 (0.64 to 1.48) 0.902
Rosiglitazone combination 83 1.06 (0.84 to 1.33) 0.610
Pioglitazone alone and combined 24 0.78 (0.52 to 1.17) 0.224
Other drugs and combination 793 1.13 (1.02 to 1.25) 0.016
Model 3 (925 790 intervals):
First generation sulphonylureas 27 1.36 (0.91 to 2.02) 0.130
Second generation sulphonylureas 365 1.09 (0.94 to 1.27) 0.266
Rosiglitazone 9 0.79 (0.41 to 1.53) 0.485
Rosiglitazone combination 29 0.82 (0.56 to 1.20) 0.310
Pioglitazone alone and combined 11 0.71 (0.39 to 1.30) 0.272
Other drugs and combinations 173 0.95 (0.79 to 1.15) 0.625
Model 1: adjusted for sex and duration of diabetes, stratified by year and quartiles of age at treatment. Model
2: model 1 plus previous peripheral arterial disease, previous cardiovascular disease, previous heart failure,
aspirin, statin or fibrate, diuretics, calcium channel blockers, spironolactone, β adrenergic antagonists,
angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, nitrates, steroids, non-steroidal
anti-inflammatory drugs, digoxin, and any previous complications from diabetes. Model 3: model 2 plus
cholesterol concentration, body mass index, HbA1c level, creatinine concentration, albumin concentration,
systolic blood pressure, and smoking.
RESEARCH
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tive results were also possible owing to the reduction
insample size in the analyses adjusted for multiple cov-
ariates(model3)wherelargenumberswithmissingdata
were excluded. Missing values in model 3 are assumed
tobemissingatrandom,sincesimilarpatientcharacter-
istics were shown in intervals with missing and non-
missing values. Intervals missing not at random might
affectthevalidityofresultspresentedformodel3,
24and
thus these analyses need to beinterpreted with caution.
A further issue is that during the period of the study
noticeable falls in cardiovascular disease rates took
place in the UK. This should not affect comparisons
of sulphonylurea treatment with metformin, as both
were routinely prescribed antidiabetes treatments in
the UK throughout the period, nor of rosiglitazone
with pioglitazone; however, it may affect comparisons
of the thiazolidinediones with metformin, since the
thiazolidinediones were not introduced into the UK
until2000.Weaddressedthisconcernbybothstratify-
ing by calendar year in all our analyses and restricting
analysesto2000onwards;thisdidnotmateriallyaffect
our findings.
Results in context
Sulphonylureas
Monotherapy with either first or second generation
sulphonylureas was associated with an excess risk of
mortality.Concernsaboutthesafetyofsulphonylureas
were first raised by the University Group Diabetes
Study, which showed increased numbers of deaths
from cardiovascular disease among users of
tolbutamide.
25 More recently, increased risk of all
cause mortality by 43% and cardiovascular disease
mortality by 70% have been reported among users of
sulphonylureascomparedwith metformin,
8 consistent
with other observational studies.
2627 These findings
contrast with results of the United Kingdom Prospec-
tive Diabetes Study, where there was no increase in
cardiovascular events or death with sulphonylurea
use compared with a conventional diet group among
non-obese people (despite greater weight gain and
higher insulin plasma concentrations with sulpho-
nylurea therapy).
28 However, among a subgroup of
obese participants randomised to metformin, sulpho-
nylureas, insulin, or conventional therapy in the Uni-
ted Kingdom Prospective Diabetes Study, metformin
wasassociatedwitha significantlylowerallcausemor-
tality than in the groups assigned intensive therapy
withsulphonylureas(P=0.021).
29AlthoughADiabetes
Outcome Progression Trial (ADOPT) did not find a
difference in cardiovascular event rates between
groups treated with glibenclamide or metformin, the
comparison had low power as it was not part of the
study design.
30 Our study extends the evidence, sug-
gesting higher mortality with sulphonylurea use than
metformin use, among unselected patients attending
general practice.
Themechanismbywhichcommonlyprescribedsul-
phonylureas (such as glibenclamide) may adversely
affect cardiovascular risk and mortality is speculative,
but a previously reported dose-response relation sug-
gests a direct drug action.
31 Sulphonylureas bind to a
regulatory subunit of the inward rectifier potassium
(KATP) channel, leading to an increase in intracellular
potassium ion concentrations, the opening of voltage
gated calcium channels, and an influx of calcium ions.
In pancreatic β cells this promotes insulin secretion,
but inhibition of KATP channels in cardiac myocytes
and vascular smooth muscle cells impairs ischaemic
preconditioning, a mechanismfor protecting the myo-
cardium from ischaemic injury.
32
Thiazolidinediones
We did not find evidence of an excess risk of myo-
cardial infarction associated with rosiglitazone com-
pared with metformin use. A meta-analysis of small
clinical trials reported a significant 43% increased risk
of myocardial infarction among rosiglitazone users
comparedwithotherdruggroups,
3althoughreanalysis
ofthesedatayieldednon-significantresults.
5Although
anothermeta-analysisreporteda31%increasedriskin
ischaemic heart disease, the risk for a cardiovascular
composite end point was not significantly increased.
33
Both meta-analyses had limitations, including short
follow-up, low event rates, no time to event data,
incompleteoutcomeascertainment,andheterogeneity
of effects between the combined studies, and concerns
have been raised about the ability of such meta-
Table 3 |Risk of a first episode of congestive heart failure among patients receiving
rosiglitazone, pioglitazone, sulphonylureas, and other drugs and combinations compared
with patients receiving metformin alone
Models and treatments No of events Hazard ratio (95% CI) P value
Model 1 (2 673 904 intervals):
First generation sulphonylureas 520 1.46 (1.32 to 1.63) <0.001
Second generation sulphonylureas 3276 1.30 (1.22 to 1.38) <0.001
Rosiglitazone 38 1.00 (0.72 to 1.38) 0.990
Rosiglitazone combination 125 1.31 (1.09 to 1.58) 0.004
Pioglitazone alone and combined 48 1.18 (0.88 to 1.57) 0.270
Other drugs and combinations 1345 1.16 (1.08 to 1.26) <0.001
Model 2 (2 673 904 intervals):
First generation sulphonylureas 520 1.29 (1.17 to 1.44) <0.001
Second generation sulphonylureas 3276 1.19 (1.12 to 1.27) <0.001
Rosiglitazone 38 1.07 (0.77 to 1.48) 0.688
Rosiglitazone combination 125 1.27 (1.06 to 1.53) 0.011
Pioglitazone alone and combined 48 1.10 (0.83 to 1.47) 0.512
Other drugs and combinations 1345 1.08 (1.00 to 1.17) 0.043
Model 3 (909 367 intervals):
First generation sulphonylureas 29 1.01 (0.70 to 1.47) 0.941
Second generation sulphonylureas 557 1.18 (1.04 to 1.34) 0.011
Rosiglitazone 10 0.61 (0.33 to 1.15) 0.128
Rosiglitazone combination 51 1.21 (0.91 to 1.63) 0.194
Pioglitazone alone and combined 24 1.17 (0.77 to 1.77) 0.456
Other drugs and combinations 227 1.06 (0.90 to 1.24) 0.505
Model 1: adjusted for sex and duration of diabetes, stratified by year and quartiles of age at treatment. Model
2: model 1 plus previous peripheral arterial disease, previous cardiovascular disease, previous heart failure,
aspirin, statin or fibrate, diuretics, calcium channel blockers, spironolactone, β adrenergic antagonists,
angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, nitrates, steroids, non-steroidal
anti-inflammatory drugs, digoxin, and any previous complications from diabetes. Model 3: model 2 plus
cholesterol concentration, body mass index, HbA1c level, creatinine concentration, albumin concentration,
systolic blood pressure, and smoking.
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RECORD (Rosiglitazone Evaluated for Cardio-
vascular outcomes in Oral agent combination therapy
for type 2 Diabetes) is an ongoing trial among 4447
patients with type 2 diabetes, designed to compare
theeffectsofrosiglitazoneincombinationwithmetfor-
min or sulphonylurea use compared with metformin
and sulphonylureas in relation to cardiovascular dis-
ease. In a recent analysis by these researchers, over
5.5 years of follow-up, risks between the two groups
were similar for the primary end point of death from
cardiovascular causes or admission to hospital for a
cardiovascular event (hazard ratio 0.99, 0.85 to
1.16).
4Inthesameanalysis,findingswereinconclusive
for myocardial infarction, for which a non-significant
increasefortherosiglitazonegroupwasreported(1.14,
0.80 to 1.63). A further meta-analysis including the
results from an interim analysis by RECORD, the
ADOPT and DREAM (Diabetes Reduction Assess-
ment with Ramipril and Rosiglitazone Medication)
clinical trials, and all small trials included in the pre-
vious meta-analysis,
3 again suggested rosiglitazone
was associated with an increased risk of myocardial
infarction (odds ratio 1.33, 95% confidence interval
1.02 to 1.72).
35 Previous observational data are also
conflicting;a significant80%excessriskofmyocardial
infarction was reported among elderly patients asso-
ciated with rosiglitazone use compared with other
oral hypoglycaemic agent combination therapies,
7
whereas two other studies in patients with diabetes
did not show an increased risk.
1314 Overall, to date
there is no clear or consistent evidence on the possible
cardiovascular benefits or harms of rosiglitazone ther-
apy, and results of clinical trials are awaited.
The observed excess risk of congestive heart failure
associated with rosiglitazone or pioglitazone use com-
paredwithmetforminaloneaccordswithpreviousevi-
dencefromclinicaltrialsandobservationalstudies.
2436
In the present study, pioglitazone was associated with
lowermortalitythanmetformin.Ourresultsforpiogli-
tazone are in good agreement with those from the
PROspective PioglitAzone Clinical Trial In Macro-
Vascular Events Study (PROACTIVE) trial, the lar-
gest randomised clinical trial of pioglitazone on
cardiovascular disease reported to date.
37 Their find-
ings showed that pioglitazone non-significantly
reduced the risk of the composite primary end point
of all macrovascular events and significantly reduced
the risk of the predefined secondary end point of all
cause mortality, myocardial infarction, or stroke
(hazard ratio 0.84, 95% confidence interval 0.72 to
0.98).
37Overall,thetrialdatasuggestapossiblecardio-
vascular protective effect of pioglitazone despite the
increased risk of heart failure.
6
In our study, mortality associated with pioglitazone
was significantly lower than with rosiglitazone.
Although both drugs are approved as “highly selec-
tive”peroxisomeproliferatoractivatedreceptorγago-
nists, recent studies suggest that pioglitazone represses
key endothelial and hepatic inflammatory responses
through peroxisome proliferator activated receptor α,
an effect not apparently shared by rosiglitazone.
38
Furthermore, the molecular mechanisms underlying
peroxisomeproliferatoractivatedreceptorγactivation
are complex, involving heterodimerisation, corepres-
sors, and coactivators; minor differences in the ligand
structureofperoxisomeproliferatoractivatedreceptor
γ could result in significant differences in target gene
response.
39 Such pharmacological differences may
translate into a differential effect on cardiovascular
protection.
40-43 It is already reported that pioglitazone
has a more favourable effect on triglycerides and high
density lipoprotein cholesterol concentrations than
rosiglitazone.
44 Pioglitazone has been shown to
decrease the rate of progression of carotid intima
media thickness and of coronary atherosclerosis,
4546
suggesting a possible role in slowing the development
of atherosclerotic plaque.
Conclusions and clinical implications
The sulphonylureas, along with metformin, have long
been considered the mainstay of drug treatment for
type 2 diabetes. Our findings suggest a relatively unfa-
vourableriskprofileofsulphonylureascomparedwith
metformin. This is consistent with the recommenda-
tions of the American Diabetes Association and Inter-
nationalDiabetes Federationthat favourmetforminas
the initial treatment for type 2 diabetes.
2122 Within
class differences in risk among the sulphonylureas
Table 4 |Risk for all cause mortality among patients receiving rosiglitazone, pioglitazone,
sulphonylureas, and other drugs and combinations compared with patients receiving
metformin alone
Models and treatments No of events Hazard ratio (95% CI) P value
Model 1 (2 842 504 intervals):
First generation sulphonylureas 1341 1.61 (1.49 to 1.74) <0.001
Second generation sulphonylureas 9606 1.55 (1.48 to 1.62) <0.001
Rosiglitazone 83 1.00 (0.78 to1.28) 0.990
Rosiglitazone combination 244 0.80 (0.70 to 0.93) 0.003
Pioglitazone alone and combined 71 0.61 (0.47 to 0.80) 0.0003
Other drugs and combinations 3291 1.03 (0.98 to 1.09) 0.271
Model 2 (2 842 504 intervals):
First generation sulphonylureas 1341 1.43 (1.33 to 1.54) <0.001
Second generation sulphonylureas 9606 1.40 (1.34 to 1.47) <0.001
Rosiglitazone 83 0.92 (0.72 to 1.17) 0.489
Rosiglitazone combination 244 0.88 (0.76 to 1.02) 0.078
Pioglitazone alone and combined 71 0.62 (0.48 to 0.81) 0.0004
Other drugs and combinations 3291 1.01 (0.96 to 1.07) 0.664
Model 3 (928 702 intervals):
First generation sulphonylureas 101 1.37 (1.11 to 1.71) 0.0003
Second generation sulphonylureas 1379 1.24 (1.14 to 1.35) <0.001
Rosiglitazone 34 1.07 (0.77 to 1.49) 0.740
Rosiglitazone combination 89 0.88 (0.71 to 1.09) 0.070
Pioglitazone alone and combined 31 0.69 (0.49 to 0.98) 0.024
Other drugs and combinations 539 0.99 (0.89 to 1.11) 0.927
Model 1: adjusted for sex and duration of diabetes, stratified by year and quartiles of age at treatment. Model
2: model 1 plus previous peripheral arterial disease, previous cardiovascular disease,previous heart failure,
aspirin, statin or fibrate, diuretics, calcium channel blockers, spironolactone, β adrenergic antagonists,
angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, nitrates, steroids, non-steroidal
anti-inflammatory drugs, digoxin, and any previous complications from diabetes. Model 3: model 2 plus
cholesterol concentration, body mass index, HbA1c level, creatinine concentration, albumin concentration,
systolic blood pressure, and smoking.
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reports of an excess risk of myocardial infarction asso-
ciated with rosiglitazone compared with metformin.
Pioglitazone was associated with reduced all cause
mortality compared with metformin, and it had a
favourable risk profile compared with rosiglitazone,
which requires replication in other studies. This may
have implications for prescribing within this class of
drugs.
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